(858) 412-4156

site-logo
  • About
    • Company
    • Technology
    • Business Development
    • Contact
  • Advisor
    • Scientific Advisory Board
  • Pipeline
    • Full Pipeline
    • RBC Nanosponge
      • MRSA Pneumonia
      • MRSA Vaccine
      • Diabetic Foot Ulcer
    • Macrophage Nanosponge
      • Sepsis
      • Cytokine Release Syndrome (CRS)
      • COVID-19
      • Inflammatory Bowel Disease
      • Arthritis
  • News
  • Career
  • Contact
featured-generic.jpg

Cellics Announces the Receipt of CARB-X Award of Up to US$15 Million

October 24, 2020

San Diego, CA (October 21st) – Cellics announced today that it has received a CARB-X Award of up to US$15 Million to develop a new treatment for sepsis caused by drug-resistant Gram-positive and Gram-negative bacteria. The award will allow Cellics to advance its highly versatile platform to treat not only sepsis but other conditions with unmet medical needs such as post CAR-T Cytokine Release Syndrome (CRS) and COVID-19.

– CARB-X News Link

– UCSD News Link

Category: Awards and Recognition

Categories

Archives

Our Mission

Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines. We strive to develop more effective and safer therapeutics and vaccines for diseases and unmet medical needs.

Our Info

11588 Sorrento Valley Rd.
Suite #20
San Diego, CA 92121

(858) 412-4156

info@cellics.com


Locate Us

Copyright 2022 © Cellics Therapeutics All rights reserved. Privacy Policy Developed by TinyFrog Technologies